IMAC Holdings, Inc. Launches E-Commerce Website for Vitamin and Supplement Line
03 Novembre 2022 - 1:30PM
IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the
“Company”), announces today it has launched an e-commerce platform
to retail its vitamin and supplement products to consumers
nationwide. IMAC recently launched Vita Eternum, an organic,
whole-food supplement line using a “seed to bottle” manufacturing
process which can now be purchased online at www.vitaeternum.com.
The Vita Eternum vitamin and supplement product
line includes USDA certified organic Sleep and Stress ashwagandha,
Women’s Multivitamin, and Men’s Multivitamin as well as an
unflavored Multi Collagen Protein and Back Multivitamin. The Vita
Eternum products retail between $29 and $49 per unit.
“We are excited about expanding the availability
of our Vita Eternum product to consumers seeking quality organic
supplements online,” said Jeff Ervin, Chief Executive Officer. “Not
only does the supplement line align with the health interests of
the average IMAC patient, but retailing the product online also
allows us to expand our consumer universe through wholesale and
affiliate partners.”
IBISWorld estimates that the domestic vitamin
and supplement market will generate $37.2 billion in annual sales
in 2022.
About IMAC Holdings, Inc.
IMAC Holdings owns and manages health and
wellness centers that deliver sports medicine, orthopedic care, and
restorative joint and tissue therapies for movement restricting
pain and neurodegenerative diseases. IMAC is comprised of
three business segments: outpatient medical centers, The Back
Space, and a clinical research division. With treatments to address
both young and aging populations, IMAC Holdings owns or
manages outpatient medical clinics that deliver regenerative
rehabilitation services as a minimally invasive approach to acute
and chronic musculoskeletal and neurological health problems.
IMAC’s The Back Company retail spinal health and wellness treatment
centers deliver chiropractic care within Walmart locations. IMAC’s
research division is currently conducting a Phase I clinical trial
evaluating a mesenchymal stem cell therapy candidate for
bradykinesia due to Parkinson’s disease. For more information
visit www.imacholdings.com.
###
Safe Harbor Statement
This press release contains forward-looking
statements. These forward-looking statements, and terms such as
“anticipate,” “expect,” “believe,” “may,” “will,” “should” or other
comparable terms, are based largely
on IMAC's expectations and are subject to a number of
risks and uncertainties, certain of which are
beyond IMAC's control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, risks and uncertainties associated with its
ability to maintain and grow its business, variability of operating
results, its ability to maintain and enhance its brand, its
development and introduction of new products and services, the
successful integration of acquired companies, technologies and
assets, marketing and other business development initiatives,
competition in the industry, general government regulation,
economic conditions, dependence on key personnel, the ability to
attract, hire and retain personnel who possess the skills and
experience necessary to meet customers’ requirements, and its
ability to protect its intellectual
property. IMAC encourages you to review other factors
that may affect its future results in its registration statement
and in its other filings with the Securities and Exchange
Commission. In light of these risks and uncertainties, there can be
no assurance that the forward-looking information contained in this
press release will in fact occur.
IMAC Press Contact:Laura Fristoelfristoe@imacrc.com
IMAC (NASDAQ:IMACW)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
IMAC (NASDAQ:IMACW)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024